2018 ANNUAL MEDICAL REPORT HIGHLIGHTS TRANSFORMATION OF KIDNEY CARE | FMCNA
WALTHAM, Mass., June 26, 2018Ģý, the leading provider of kidney care products and services, today announced the publication of its, offering expert insights on the latest science and innovation that is transforming clinical practice and patient care. Entitled ĢýGo Further, Faster: Translating Science Into Practice,Ģý this yearĢýs report features insights from more than two dozen FMCNA and Ģý leaders, researchers, scientists, mathematicians and caregivers from across the enterprise. The collective content demonstrates the power of uniting people and possibility toward one unified purpose: our patients.
In an introductory whitepaper, Frank Maddux, MD, FACP, FMCNAĢýs Chief Medical Officer and Executive Vice President for Clinical and Scientific Affairs, offers a visionary look into four key concepts shaping the evolution of:
- Translating science into practice, one of FMCNAĢýs greatest competitive advantages;
- The benefits of a reclassification of kidney disease;
- Evolving the elements and processes of personalized kidney care; and
- Recognizing the health impact of social determinants.
ĢýOur unmatched ability to translate science into practice and ĢýĢýs vertically-integrated structure ensures we always consider the clinical, behavioral and environmental factors impacting our patientsĢý lives,Ģý said Dr. Maddux. ĢýEmbracing new science and innovation for the benefit of our patients is one of the many ways we are working to reimagine kidney care. This yearĢýs annual medical report reflects the depth of our expertise and demonstrates our commitment to setting the industry standard for patient-centered care.Ģý
Additional highlights from the report include:
- How technology and care coordination are driving the growth of home therapies and the ability for patients to choose dialysis care outside the walls of a dialysis clinic;
- How using complex mathematics and science drives innovations, such as creating a virtual cinacalcet clinical trial to create computerized mathematical physiologic models Ģý avatars Ģý of patients;
- Best practices in antibiotic stewardship to help minimize the unintended consequences of antibiotic usage in patients with end stage renal disease;
- How the companyĢýs advanced capabilities to Ģýlisten through numbersĢý is driving clinical innovation by going from descriptive to prescriptive analytics Ģý and thus creating innovative predictive models to improve patient care; and
- How FMCNAĢýs focus on emerging science, such as bioengineered vessels, has immediate potential to address the current limitations in dialysis vascular access and serve as a more cost-effective, reliable and safe alternative to arteriovenous fistulas (AVFs), AV grafts and central venous catheters.
Business units represented in the 2018 Annual Medical Report include FMCNA (Corporate); Fresenius Kidney Care; FreseniusRx; Fresenius Health Partners; Renal Therapies Group; Azura Vascular Care; Frenova Renal Research; Renal Research Institute and Acumen Physician Solutions.
Read the full report.
Ģý Ģý North America
Ģý North America is the premier health care company focused on providing the highest quality care to people with renal and other chronic conditions. Through its industry-leading network of dialysis facilities, outpatient cardiac and vascular labs, and urgent care centers, as well as the countryĢýs largest practice of hospitalist and post-acute providers, Ģý North America provides coordinated health care services at pivotal care points for hundreds of thousands of chronically ill customers throughout the continent. As the worldĢýs largest fully integrated renal company, it offers specialty pharmacy and laboratory services, and manufactures and distributes the most comprehensive line of dialysis equipment, disposable products and renal pharmaceuticals. For more information, visit the FMCNA website at.
